MA34296B1 - Composition retard injectable antipsychotique - Google Patents

Composition retard injectable antipsychotique

Info

Publication number
MA34296B1
MA34296B1 MA35428A MA35428A MA34296B1 MA 34296 B1 MA34296 B1 MA 34296B1 MA 35428 A MA35428 A MA 35428A MA 35428 A MA35428 A MA 35428A MA 34296 B1 MA34296 B1 MA 34296B1
Authority
MA
Morocco
Prior art keywords
composition
biodegradable
injectable
retardant
rates
Prior art date
Application number
MA35428A
Other languages
English (en)
Inventor
Aduriz Ibon Gutierro
Ochoa Maria Teresa Gomez
Original Assignee
Rovi Lab Farmaceut Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43301889&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34296(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rovi Lab Farmaceut Sa filed Critical Rovi Lab Farmaceut Sa
Publication of MA34296B1 publication Critical patent/MA34296B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE UNE COMPOSITION QUI PEUT ÊTRE UTILISÉE POUR ADMINISTRER UN MÉDICAMENT ANTIPSYCHOTIQUE TEL QUE LA RISPÉRIDONE SOUS FORME D'UN IMPLANT BIODÉGRADABLE DE FORMATION IN-SITU POUR LA LIBÉRATION PROLONGÉE ASSURANT DES TAUX PLASMATIQUES THÉRAPEUTIQUES DÈS LE PREMIER JOUR. LA COMPOSITION SE PRÉSENTE SOUS LA FORME D'UNE SUSPENSION MÉDICAMENTEUSE SUR UN COPOLYMÈRE OU UNE SOLUTION DE COPOLYMÈRES BIODÉGRADABLE ET BIOCOMPATIBLE UTILISANT DES SOLVANTS MISCIBLES QUI EST ADMINISTRÉE SOUS FORME LIQUIDE. UNE FOIS LA COMPOSITION EN CONTACT AVEC LES LIQUIDES CORPORELS, LA MATRICE POLYMÈRE DURCIT, RETENANT LE MÉDICAMENT, FORMANT UN IMPLANT SOLIDE OU SEMI-SOLIDE QUI LIBÈRE LE MÉDICAMENT EN CONTINU. DES TAUX PLASMATIQUES THÉRAPEUTIQUES DU MÉDICAMENT PEUVENT ÊTRE OBTENUS DÈS LE PREMIER JOUR JUSQU'AU MOINS 14 JOURS OU PLUS.
MA35428A 2010-05-31 2011-05-31 Composition retard injectable antipsychotique MA34296B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10382154.2A EP2394664B1 (fr) 2010-05-31 2010-05-31 Compositions pour implants biodégradables in situ injectables
PCT/EP2011/059000 WO2011151355A1 (fr) 2010-05-31 2011-05-31 Composition retard injectable antipsychotique

Publications (1)

Publication Number Publication Date
MA34296B1 true MA34296B1 (fr) 2013-06-01

Family

ID=43301889

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35428A MA34296B1 (fr) 2010-05-31 2011-05-31 Composition retard injectable antipsychotique

Country Status (32)

Country Link
US (2) US10085936B2 (fr)
EP (2) EP2394664B1 (fr)
JP (1) JP5882993B2 (fr)
KR (1) KR101784330B1 (fr)
CN (1) CN103002917B (fr)
AP (1) AP3524A (fr)
AU (1) AU2011260318B2 (fr)
BR (1) BR112012030686B1 (fr)
CA (1) CA2800111C (fr)
CL (1) CL2012003350A1 (fr)
CY (2) CY1117964T1 (fr)
DK (2) DK2394664T3 (fr)
EA (1) EA024155B1 (fr)
ES (2) ES2589106T3 (fr)
HR (2) HRP20161049T1 (fr)
HU (2) HUE029895T2 (fr)
IL (1) IL223129A (fr)
LT (2) LT2394664T (fr)
MA (1) MA34296B1 (fr)
ME (1) ME02501B (fr)
MX (1) MX338373B (fr)
MY (1) MY161930A (fr)
NZ (1) NZ604342A (fr)
PL (2) PL2394664T3 (fr)
PT (2) PT2394664T (fr)
RS (1) RS55190B1 (fr)
SG (1) SG185775A1 (fr)
SI (2) SI2394664T1 (fr)
SM (2) SMT201600320B (fr)
UA (1) UA108885C2 (fr)
WO (1) WO2011151355A1 (fr)
ZA (1) ZA201209346B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
NZ581862A (en) 2007-05-25 2012-06-29 Tolmar Therapeutics Inc Injectable subcutaneous formulation comprising risperidone capable of forming a solid, microporous implant in a patient
EP2394663B1 (fr) 2010-05-31 2021-10-13 Laboratorios Farmaceuticos Rovi, S.A. Compositions pour implants biodégradables in situ injectables
US10350159B2 (en) * 2010-05-31 2019-07-16 Laboratories Farmacéuticos Rovi, S.A. Paliperidone implant formulation
US10285936B2 (en) 2010-05-31 2019-05-14 Laboratorios Farmacéuticos Rovi, S.A. Injectable composition with aromatase inhibitor
US10335366B2 (en) * 2010-05-31 2019-07-02 Laboratorios Farmacéuticos Rovi, S.A. Risperidone or paliperidone implant formulation
SI2394664T1 (sl) 2010-05-31 2016-10-28 Laboratorios Farmaceuticos Rovi, S.A. Antipsihotični depojski sestavek za injiciranje
US10463607B2 (en) 2010-05-31 2019-11-05 Laboratorios Farmaceutics Rofi S.A. Antipsychotic Injectable Depot Composition
US10881605B2 (en) 2010-05-31 2021-01-05 Laboratorios Farmaceuticos Rovi, S.A. Methods for the preparation of injectable depot compositions
PL2529757T3 (pl) * 2011-05-31 2014-04-30 Farm Rovi Lab Sa Formulacja implantu zawierającego paliperydon
RS62059B1 (sr) * 2011-05-31 2021-07-30 Laboratorios Farmaceuticos Rovi S A Kompozicija implanta risperidona i/ili paliperidona
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
BR112015022023B1 (pt) 2013-03-11 2022-12-06 Durect Corporation Composição de liberação controlada injetável compreendendo transportador líquido de alta viscosidade
WO2016199170A2 (fr) * 2015-06-10 2016-12-15 Cipla Limited Particules de palmitate de palipéridone et compositions à base de celles-ci
CA3057438A1 (fr) 2017-03-20 2018-09-27 Teva Pharmaceuticals International Gmbh Formulations d'olanzapine a liberation prolongee
CN109589304A (zh) * 2017-10-01 2019-04-09 万特制药(海南)有限公司 利培酮口服溶液及其制备方法
CN110420212A (zh) * 2019-08-19 2019-11-08 韩自勤 一种用于治疗精神分裂症组合物及其制备方法
TW202313047A (zh) 2021-09-21 2023-04-01 西班牙商禾霏藥品實驗室有限公司 抗精神病可注射儲積型組合物

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
BE758156R (fr) 1970-05-13 1971-04-28 Ethicon Inc Element de suture absorbable et sa
US4389330A (en) 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4523591A (en) 1982-10-22 1985-06-18 Kaplan Donald S Polymers for injection molding of absorbable surgical devices
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5620700A (en) 1990-10-30 1997-04-15 Alza Corporation Injectable drug delivery system and method
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
JP3645906B2 (ja) 1993-11-19 2005-05-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ マイクロカプセル封入された３−ピペリジニル−置換１，２−ベンズイソオキサゾール類及び１，２−ベンズイソチアゾール類
EP0949905B1 (fr) 1996-12-20 2001-07-18 Alza Corporation Composition de gel injectable a effet retard et son procede de preparation
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6331317B1 (en) * 1999-11-12 2001-12-18 Alkermes Controlled Therapeutics Ii Inc. Apparatus and method for preparing microparticles
AU2001237221A1 (en) * 2000-01-11 2001-07-24 Roland Bodmeier Implants, particles
US6604561B2 (en) * 2000-02-11 2003-08-12 Medical Instill Technologies, Inc. Medicament vial having a heat-sealable cap, and apparatus and method for filling the vial
DK1539101T3 (da) * 2002-07-31 2009-04-27 Alza Corp Injicerbare, multi-modale polymere depotsammens tninger og anvendelser deraf
US7658998B2 (en) * 2003-01-22 2010-02-09 Alkermes Controlled Therapeutics, Inc. Method of preparing sustained release microparticles
US20050003007A1 (en) 2003-07-02 2005-01-06 Michele Boix Method of sterilization of polymeric microparticles
JP2008518881A (ja) * 2003-07-18 2008-06-05 オークウッド ラボラトリーズ，エル．エル．シー． 高分子組成物中の高分子の分子量低下、不純物形成およびゲル化の防止
US8221778B2 (en) 2005-01-12 2012-07-17 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
DE102005031868A1 (de) * 2005-07-04 2007-01-18 Biotronik Vi Patent Ag Arzneimitteldepot zur parenteralen, insbesondere intravaskulären Arzneimittelfreisetzung
US8852638B2 (en) * 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
US8076448B2 (en) 2006-10-11 2011-12-13 Tolmar Therapeutics, Inc. Preparation of biodegradable polyesters with low-burst properties by supercritical fluid extraction
FR2908775B1 (fr) * 2006-11-17 2012-08-31 Biomatlante Hydrogel et ses applications biomedicales
ES2550014T3 (es) 2007-02-15 2015-11-03 Tolmar Therapeutics, Inc. Poli-(lactida/glicolida) de descarga lenta y métodos para producir polímeros
CN101677952B (zh) * 2007-05-18 2012-12-05 杜雷科特公司 改进的贮库制剂
NZ581862A (en) * 2007-05-25 2012-06-29 Tolmar Therapeutics Inc Injectable subcutaneous formulation comprising risperidone capable of forming a solid, microporous implant in a patient
WO2009060473A2 (fr) * 2007-11-06 2009-05-14 Panacea Biotec Limited Compositions injectables, procédés et utilisations correspondantes
MX347056B (es) * 2008-08-12 2017-04-10 Novartis Ag Composiciones farmaceuticas.
EP2394663B1 (fr) 2010-05-31 2021-10-13 Laboratorios Farmaceuticos Rovi, S.A. Compositions pour implants biodégradables in situ injectables
US10335366B2 (en) 2010-05-31 2019-07-02 Laboratorios Farmacéuticos Rovi, S.A. Risperidone or paliperidone implant formulation
US10285936B2 (en) 2010-05-31 2019-05-14 Laboratorios Farmacéuticos Rovi, S.A. Injectable composition with aromatase inhibitor
US10350159B2 (en) 2010-05-31 2019-07-16 Laboratories Farmacéuticos Rovi, S.A. Paliperidone implant formulation
SI2394664T1 (sl) 2010-05-31 2016-10-28 Laboratorios Farmaceuticos Rovi, S.A. Antipsihotični depojski sestavek za injiciranje
RS62059B1 (sr) 2011-05-31 2021-07-30 Laboratorios Farmaceuticos Rovi S A Kompozicija implanta risperidona i/ili paliperidona
PL2529757T3 (pl) 2011-05-31 2014-04-30 Farm Rovi Lab Sa Formulacja implantu zawierającego paliperydon

Also Published As

Publication number Publication date
AP3524A (en) 2016-01-11
UA108885C2 (uk) 2015-06-25
HRP20161049T1 (hr) 2016-12-30
JP2013528612A (ja) 2013-07-11
AU2011260318B2 (en) 2014-11-27
US20130171202A1 (en) 2013-07-04
PT2575890T (pt) 2016-09-06
SG185775A1 (en) 2013-01-30
KR101784330B1 (ko) 2017-10-11
US10182982B2 (en) 2019-01-22
BR112012030686A2 (pt) 2020-08-25
CY1117964T1 (el) 2017-05-17
US10085936B2 (en) 2018-10-02
CL2012003350A1 (es) 2013-10-18
KR20130118742A (ko) 2013-10-30
MX338373B (es) 2016-04-13
PL2394664T3 (pl) 2016-12-30
AU2011260318A1 (en) 2013-01-10
CY1117969T1 (el) 2017-05-17
MY161930A (en) 2017-05-15
EP2394664A1 (fr) 2011-12-14
IL223129A0 (en) 2013-02-03
SI2394664T1 (sl) 2016-10-28
NZ604342A (en) 2014-11-28
EA201201569A1 (ru) 2013-04-30
PT2394664T (pt) 2016-09-06
IL223129A (en) 2016-02-29
HUE029056T2 (en) 2017-02-28
HUE029895T2 (en) 2017-04-28
ES2592527T3 (es) 2016-11-30
EP2394664B1 (fr) 2016-06-01
CN103002917B (zh) 2016-04-27
MX2012013937A (es) 2013-02-11
CN103002917A (zh) 2013-03-27
US20180221272A1 (en) 2018-08-09
PL2575890T3 (pl) 2016-12-30
EA024155B1 (ru) 2016-08-31
LT2575890T (lt) 2016-09-26
SMT201600321B (it) 2016-11-10
DK2394664T3 (en) 2016-09-12
AP2012006626A0 (en) 2012-12-31
EP2575890A1 (fr) 2013-04-10
DK2575890T3 (en) 2016-09-12
ME02501B (fr) 2017-02-20
RS55190B1 (sr) 2017-01-31
HRP20161100T1 (hr) 2016-11-04
SI2575890T1 (sl) 2016-10-28
CA2800111A1 (fr) 2011-12-08
JP5882993B2 (ja) 2016-03-09
CA2800111C (fr) 2018-05-22
ZA201209346B (en) 2013-08-28
WO2011151355A1 (fr) 2011-12-08
BR112012030686B1 (pt) 2022-11-01
EP2575890B1 (fr) 2016-06-01
ES2589106T3 (es) 2016-11-10
SMT201600320B (it) 2016-11-10
LT2394664T (lt) 2016-09-26

Similar Documents

Publication Publication Date Title
MA34296B1 (fr) Composition retard injectable antipsychotique
RU2470642C2 (ru) Аналоги птерина для лечения состояния, чувствительного к вн4
KR20180080189A (ko) 이상 염증 반응과 연관된 질환을 치료하기 위한 방법 및 조성물
MD20070267A (en) Gastroresistant pharmaceutical formulation containing rifaximin
MA32692B1 (fr) Procede de liberation d'une composition pharmaceutique a un patient qui en a besoin
CY1109425T1 (el) Φαρμακευτικες συνθεσεις για τη χορηγηση με ελεγχομενη αποδεσμευση βιολογικα δραστικων ενωσεων
MY167123A (en) Conveniently implantable sustained release drug compositions
BR0213143A (pt) Composições lìquidas para administração oral contendo guaifenesina e um copolìmero de bloco polioxialquileno
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
BR0308137A (pt) Formulações de droga de liberação constante contendo um peptìdeo veìculo
JP2008513506A5 (fr)
MA44206B1 (fr) Comprimé orodispersible comprenant estetrol
NZ595127A (en) Stable pharmaceutical composition for atherosclerosis
MY147310A (en) A solid pharmaceutical composition containing 2-ethoxy-1-{ [2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl) biphenyl-4-yl]methyl}-1h-benzimidazole-7-carboxylic acid or a salt thereof, a fat and oil-like substace having low melting point and a low viscosity binder
MA33533B1 (fr) Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles
FR19C1030I1 (fr) Systeme d'administration de medicament pour administrer des substances pharmaceutiquement actives pauvrement hydrosolubles
JP2015531373A5 (fr)
MX2019001596A (es) Uso y dosificacion de agentes terapeuticos para endometriosis.
TW200815410A (en) Compositions and methods for treating, controlling, reducing, or ameliorating infections and sequelae thereof
Thomsen et al. Effects of acute and chronic treatments with dopamine D2 and D3 receptor ligands on cocaine versus food choice in rats
MA33602B1 (fr) Composition pharmaceutique permettant de prévenir ou de traiter l'arthrite rhumatoïde, contenant du rébamipide
BRPI0513222A (pt) agente para promoção de recuperação de disfunção após o inicio de doença neurológica central
PE20130782A1 (es) Composiciones farmaceuticas que consisten de paracetamol y el proceso para la preparacion del mismo
RU2552290C1 (ru) Соединения опиоидных антагонистов и их применение при лечении склеродермии
TW200501946A (en) Pharmaceutical composition for the treatment of schizophrenia in a patient with overweight